<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444704</url>
  </required_header>
  <id_info>
    <org_study_id>3208A1-1002</org_study_id>
    <nct_id>NCT00444704</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females</brief_title>
  <official_title>Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Japanese Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety and tolerability of ascending
      single oral doses of PRA-027 in healthy Japanese females. The secondary purpose is to provide
      the initial pharmacokinetic and pharmacodynamic profiles of PRA-027 in healthy Japanese
      female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of this study is to asess the safety and tolerability of ascending single oral doses of PRA-027 in healthy Japanese females.</measure>
  </primary_outcome>
  <condition>Uterine Leiomyomata (Fibroids)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRA-027</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Women of nonchildbearing potential aged 20 to 64 years. Must have a negative pregnancy
             test result within 48 hours before administration of test article. Women who are
             surgically sterile must provide documentation of the procedure by an operative report
             or by ultrasound scan.

          2. Body mass index (BMI) in the range of 17.6 to 26.4 kg/m2 and body weight must be at
             least 45 kg.

          3. Healthy as determined by the investigator on the basis of screening evaluation.

        EXCLUSION CRITERIA

          1. Any significant cardiovascular, hepatic, renal, respiratory, gynecologic
             gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or
             psychiatric disease.

          2. Any history of drug abuse or admitted alcohol abuse or history of alcohol use that may
             interfere with the subject's ability to comply with the protocol requirements.

          3. Use of any investigational drug within 90 days before study day 1, use of any
             prescription drug within 30 days before study day 1, consumption of any
             caffeine-containing products (eg, coffee, tea, chocolate, or cola) or alcoholic
             beverages within 48 hours before study day 1, consumption of grapefruit or
             grapefruit-containing products within 72 hours before study day 1, use of any
             over-the-counter drugs, including herbal supplements (except for the occasional use of
             vitamins â‰¤100% of the recommended daily allowance), within 14 days before study day 1,
             or the donation of blood within 90 days before study day 1.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki Prefecture</state>
        <zip>305-0856</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>July 8, 2009</last_update_submitted>
  <last_update_submitted_qc>July 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

